Luteolin exhibits anticancer activity in colorectal cancer by inhibiting the Wnt/IGF signaling pathway while simultaneously promoting natural anti-oncogenic mechanisms, such as the pro-apoptotic pathway mediated by the expression of BAX proteins, caspase-3, -7, and -9, and the tissue inhibitor of metalloproteinases (TIMP). The gene discussed is BAX; the disease is colorectal cancer.